Role of inhibitory G protein signaling in regulating beta-cell function and survival in the type 1 diabetic state
Role of inhibitory G protein signaling in regulating beta-cell function and survival in the type 1 diabetic state
批准号:
9261945
负责人:
Rachel J Fenske
金额:
$4.4万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-01 至 2021-05-31
关键词:
AddressAdjuvantApoptosisB-LymphocytesBeta CellBiologicalBloodBlood GlucoseCell SurvivalCell physiologyCellsChronic DiseaseComplexCoupledCritical PathwaysCyclic AMPDataDiabetes MellitusDiabetes preventionDinoprostoneDiseaseFailureFamilyFinancial compensationFunctional disorderG-substrateGTP-Binding ProteinsGoalsHealthHealth Care CostsHeterotrimeric GTP-Binding ProteinsHormonesHyperglycemiaImmuneIn VitroInbred NOD MiceIndividualInfiltrationInflammationInsulinInsulin-Dependent Diabetes MellitusInternationalInterventionIslets of LangerhansLinkLongevityMaintenanceMeasuresMediatingMolecularOutcomePancreasParacrine CommunicationPathogenesisPathologyPathway interactionsPatient CarePatientsPharmacologic SubstancePhenotypePlayPreventionProductionProstaglandinsProteinsPublic HealthRegulationResistanceRoleSignal PathwaySignal TransductionSignaling ProteinStreamTestingTherapeuticUnited StatesWorkautocrinebasecell typecostdiabetes managementdiabetes mellitus therapydiabeticdiabetic patienthuman diseaseimprovedimproved outcomein vivoincretin hormoneinsulin secretionisletmouse modelnew therapeutic targetnovelnovel strategiesreceptorresponsestandard of caretype I diabetic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The International Diabetes Federation estimates the global burden of diabetes to have skyrocketed to over 387
million people with healthcare costs reaching over $612 billion in the United States alone. Diabetes
management for these individuals, particularly Type I Diabetic patients, is extremely rigorous and does not
provide an efficient means of disease maintenance. Current standard of care for patients with Type I Diabetes
is treatment with exogenous insulin, a measure, which simply put, allows patients to live normally, but does not
inherently solve any of the underlying pathologies associated with the disease. Additionally, there are very few
Type I Diabetes adjuvant therapeutics, none of which are known to improve β-cell health and function. We
have a growing body of evidence that suggests that this protein, specifically the alpha subunit (Gαz) plays a
notable role in mediating pathways regulating multiple β-cell pathologies associated with Type I Diabetes.
Therefore, our long-term goal is to fully elucidate the signaling mechanism by which Gαz acts in both normal
and diabetic β-cells, determining the steps that become dysfunctional in the diabetic state, and ultimately
modulating these steps for preventative and therapeutic purposes. The overall objective of this work, which is
the next logical step in pursuit of our goal, is to characterize the role of β-cell Gαz on the molecular and cellular
signaling pathways responsible for its impact on diabetes pathophysiology. Our central hypothesis is that
activated β-cell Gαz negatively modulates specific intracellular and autocrine/paracrine signaling pathways
critical for β-cell compensation, ultimately leading to β-cell dysfunction and loss of β-cell mass resulting in
diabetes pathogenesis. We will test our central hypothesis and, thereby, accomplish the objective of this
application, by pursuing the following two specific aims: (1) Determine the role of β-cell Gαz on β-cell
function in the Type I Diabetic condition and (2) Elucidate the effect of β-cell Gαz on signaling
pathways that mediate β-cell survival following insulitis. With the completion of these aims, we anticipate
a much more complete understanding of the role of Gαz in both healthy and diabetic β-cells. Such results are
anticipated to have an important positive outcome on the diabetes field, as Gαz is a unique player in the
integrated signaling pathways that mediate β-cell function and survival, providing a new target for developing
therapeutics for the prevention and treatment of Type I diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金